199 related articles for article (PubMed ID: 19491261)
1. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.
Cai C; Portnoy DC; Wang H; Jiang X; Chen S; Balk SP
Cancer Res; 2009 Jun; 69(12):5202-9. PubMed ID: 19491261
[TBL] [Abstract][Full Text] [Related]
2. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
6. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.
Lin HP; Ho HM; Chang CW; Yeh SD; Su YW; Tan TH; Lin WJ
FASEB J; 2019 Dec; 33(12):14653-14667. PubMed ID: 31693867
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
[TBL] [Abstract][Full Text] [Related]
8. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
9. The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.
Mandel A; Larsson P; Sarwar M; Semenas J; Syed Khaja AS; Persson JL
Mol Med; 2018 Jun; 24(1):34. PubMed ID: 30134822
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R
Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697
[TBL] [Abstract][Full Text] [Related]
11. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells.
Bonaccorsi L; Muratori M; Carloni V; Marchiani S; Formigli L; Forti G; Baldi E
Steroids; 2004 Aug; 69(8-9):549-52. PubMed ID: 15288768
[TBL] [Abstract][Full Text] [Related]
12. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.
Zheng Y; Izumi K; Yao JL; Miyamoto H
Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411
[TBL] [Abstract][Full Text] [Related]
13. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
14. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
15. The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.
Hong SK; Kim JH; Lin MF; Park JI
Exp Cell Res; 2011 Nov; 317(18):2671-82. PubMed ID: 21871886
[TBL] [Abstract][Full Text] [Related]
16. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
[TBL] [Abstract][Full Text] [Related]
19. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
